SDZ News & Analysis
2 articles
Market Mood
Sandoz (SDZ) Shares Rise 8% After Q2 Biosimilars Beat Earnings
Sandoz (SDZ) shares increased by 8% following the company's second-quarter biosimilars performance exceeding expectations. The company affirmed its full-year 2026 outlook, which provides investors clarity on future earnings potential. This announcement reflects the growing demand in the biosimilars market, which could positively impact Sandoz's market position. The performance and outlook provided by Sandoz are essential for investors to gauge the company's potential for sustained growth in the sector.
Read More: Sandoz (SDZ) Shares Rise 8% After Q2 Biosimilars Beat Earnings
Sandoz warns of cheap Chinese imports impacting antibiotic supply
Sandoz's chief executive expressed concerns that inexpensive imports from China could jeopardize Europe’s antibiotic supply. The company emphasized the need for stronger protections to maintain the continent's medicine capacity. Without these measures, there is a risk of significant supply disruptions in a critical healthcare sector. The potential impact on the pharmaceutical market could affect pricing and availability for consumers in Europe.
Read More: Sandoz warns of cheap Chinese imports impacting antibiotic supply